Menu ×

HEALTHCARE & PHARMACEUTICAL

Opioid Antagonist Market Segmentation by Drug Type (Buprenorphine, Naltrexone, Bunavail, and Others); by Route of Administration (Oral, and Parenteral) and by End User (Hospitals, Private Clinics, and Others) - Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Opioid Antagonist Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • October 02, 2017: Titan Pharmaceuticals, Inc. collaborated with Opiant Pharmaceuticals, Inc. in order to explore the development of a novel approach so as to do the prevention of opioid relapse as well as overdose in individuals with opioid use disorder.

Global Opioid Antagonist Market Highlight over 2022-2030

The global opioid antagonist market is anticipated to record a significant CAGR throughout the forecast period, i.e., 2022-2030. The market growth can be attributed to the advantages of antagonist in blocking the effects of opioids in the body. It blocks opioid by attaching to the receptors without their activation. These drugs are mainly used as antidotes in order to reverse opioid overdose and in the treatment of opioid dependence as well as alcohol dependence. These factors are predicted to boost the market growth in the upcoming years. Moreover, increasing cases of drug abuse, especially among youth, is expected to boost the market growth. According to the data by the World Health Organization (WHO), in 2019, around 180,000 deaths were directly linked to drug abuse.

Global-Opioid-Antagonist-Market-Overview

The market is segmented by drug type, into buprenorphine, naltrexone, bunavail, and others, out of which, the buprenorphine segment is anticipated to hold the largest market share over the forecast period, owing to its excellent clinical profile. This drug has a great efficiency in managing addiction, with low potential for abuse as well as relatively mild adverse effects and its favourable formulary coverage are some of the factors that can be attributed to the high adoption of this drug. CLICK TO DOWNLOAD SAMPLE REPORT  

On the basis of end-user, the market is segmented into hospitals, private clinics, and others, out of which, the hospitals segment is anticipated to garner the highest revenue during the forecast period, owing to the increasing patient pool for opium and alcohol dependency. Moreover, the critical condition of the individual addicted to drugs, and the need for specific treatment is estimated to boost the segment growth.

Major Macro-Economic Indicators Impacting the Market Growth

HealthcareAccording to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Opioid Antagonist Market Regional Synopsis

On the basis of regional analysis, the global opioid antagonist market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America is anticipated to hold the largest market share on the back of presence of nations such as the United States and Canada where there is opioid epidemic to a great extent. Furthermore, governments of the various countries in this region are introducing various policies in order to control the crisis, which is anticipated to promote the growth of the regional market. For instance, in the year 2018, government of the United States launched an awareness advertising campaign in order to combat addiction of opioid.

The market in the Asia Pacific is anticipated to hold the highest CAGR during the forecast period, owing to the rising cases of drug addiction, backed by growing population and poverty, in various developing countries. As per the data by the NIDA, in India, more than 2 million individuals suffered from opiate addiction, out of which, 25% needed immediate medical attention, in 2020.

Global-Opioid-Antagonist-Market-Share

The global opioid antagonist market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global opioid antagonist market includes the following segments:

By Drug Type

  • Buprenorphine
  • Naltrexone
  • Bunavail
  • Others

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals
  • Private Clinics
  • Others

Growth Drivers

  • Continuous Reformulation of Opioid Antagonist to Tackle Opioid Addiction
  • Reduction in Adverse Effects Associated with Opioids

Challenges

  • Difficulty During Withdrawal of The Drugs

Top Featured Companies Dominating the Market

  • Indivior PLC
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
  • Alkermes, Inc.
  • Titan Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Orexo AB
  • Camurus AB
  • Acura Pharmaceuticals, Inc.
  • BioDelivery Sciences International, Inc.
  • Collegium Pharmaceutical, Inc.
  • Daiichi Sankyo company, limited

 

 

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved